Portage Biotech Inc.will expand its clinical stage immuno-oncology pipeline with the addition of two adenosine receptor antagonists through the acquisition of Tarus Therapeutics. Publicly traded Portage, a company led by former immuno-oncology specialists who previously worked at Bristol Myers Squibb Company, will buy privately held Tarus in a stock transaction valued at around $21m upfront.
Tarus investors will also be able eligible to receive up to $32m in potential future development and sales milestone payments under the deal, which includes two clinical stage and two preclinical
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?